2011
DOI: 10.1016/j.jmb.2011.06.013
|View full text |Cite
|
Sign up to set email alerts
|

p38α MAP Kinase Dimers with Swapped Activation Segments and a Novel Catalytic Loop Conformation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
18
0

Year Published

2011
2011
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 15 publications
(18 citation statements)
references
References 41 publications
0
18
0
Order By: Relevance
“…In addition to the well-characterized activation of p38α via phosphorylation at both residues of the p38α TxY activation loop motif by dual T/Y-specific MAPK kinases, p38α is activated via a noncanonical pathway via homodimerization. 21 These data suggested that c-Abl mediates p38α activation via both canonical (Y182) and noncanonical (Y323) pathways.…”
Section: Resultsmentioning
confidence: 93%
“…In addition to the well-characterized activation of p38α via phosphorylation at both residues of the p38α TxY activation loop motif by dual T/Y-specific MAPK kinases, p38α is activated via a noncanonical pathway via homodimerization. 21 These data suggested that c-Abl mediates p38α activation via both canonical (Y182) and noncanonical (Y323) pathways.…”
Section: Resultsmentioning
confidence: 93%
“…8 ). Of note, the mechanisms of mutant-controlled energy landscape shift that can either promote or impede the swapped dimer, are not limited to Bax, but observed for other proteins, including Grb7 62 , E-cadherin 63 , p38α 64 , LRRK2 65 , Protein L 66 , SPAK 67 and cytochrome complexes 68 . This suggests that the triggering or blocking swapped protein assemblies by mutations is a general phenomenon that plays an important role in human metabolism and broadly in the cell 69 , including in membrane pores as is the case here.…”
Section: Discussionmentioning
confidence: 99%
“…[5] It has also been crystallized as ab ound ligand to Abl, BMX, BTK, EphA4,L yn, p38a,p 38MAP,a nd Src kinases. [7][8][9][10][11][12][13][14] The common manner by which it binds to each of thesek inases suggestsi t should be similar for many other kinases as well. This may,i n part, explain the sidee ffects of the compound at clinical dosage.…”
Section: Introductionmentioning
confidence: 99%